A prospective study of FOLFOX4 regimen's tolerance in the treatment of metastatic colorectal cancer

Purpose: Oxaliplatin is an effective anticancer agent in the treatment of colorectal cancer (CRC), and its usage has become widespread also in Hungary in the last few years. Between February 2003 and January 2005. we evaluated the hematological, gastrointestinal, acute and chronic neurological and other type toxicities at our department, including the dose limiting toxicities of oxaliplatin plus de Gramont regimen. Methods: We conducted a prospective analysis of 95 metastatic colorectal patients treated with FOLFOX4 regimen (OX 85mg/m2 d1, LV 200mg/m2, 5FU bolus 400mg/m2 and 22h 600mg/m2 d1–2, q2w) in metastatic…